Study guide

12.2 Electrolyte Disorders

NBME Comprehensive Basic Science Examination CBSE

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Navigation

1.1 Current Exam Facts & Administration 1.2 Content Blueprint & Physician Tasks 1.3 Scoring, Score Reports & Step 1 Readiness

2 Human Development

2.1 Embryology & Congenital Development Patterns 2.2 Normal Age-Related Findings & Well-Patient Care

3 Blood & Hematologic Disease

3.1 Hematopoiesis, RBC Disorders & Anemias 3.2 Hemostasis, Thrombosis & Coagulopathies 3.3 WBC Disorders, Leukemia & Lymphoma Mechanisms

4 Immune System

4.1 Innate & Adaptive Immunity Mechanisms 4.2 Hypersensitivity, Autoimmunity & Immunodeficiency 4.3 Transplant Immunology & Immune Pharmacology

5 Nervous System Anatomy & Disease

5.1 Neuroanatomy Localization & Pathways 5.2 Stroke, Infection, Demyelination & Trauma 5.3 Seizures, Movement Disorders & Neurodegeneration 5.4 Special Senses: Eye & Ear Mechanisms

6 Behavioral Health

6.1 Psychiatric Disorders & Diagnostic Patterns 6.2 Psychopharmacology Mechanisms 6.3 Neurotransmitters, Learning & Behavioral Science

7 Musculoskeletal System

7.1 Bone Physiology, Fracture Healing & Bone Pathology 7.2 Joint Disease, Rheumatology & Connective Tissue 7.3 Muscle, NMJ & Peripheral Nerve Disorders

8 Skin & Soft Tissue

8.1 Dermatopathology High-Yield Lesions 8.2 Inflammation, Wound Healing & Soft-Tissue Infection

9 Cardiovascular Pathophysiology

9.1 Cardiac Cycle, Hemodynamics & Murmurs 9.2 Ischemic Heart Disease & Cardiomyopathy 9.3 Congenital & Valvular Heart Disease 9.4 Vascular Pathology & Hypertension

10 Cardiovascular Pharmacology

10.1 Antihypertensives, Heart Failure & Antiarrhythmics 10.2 Antiplatelets, Anticoagulants & Lipid Drugs

11 Respiratory System

11.1 Pulmonary Mechanics & Gas Exchange 11.2 Obstructive, Restrictive & Vascular Lung Disease 11.3 Pulmonary Infections, Neoplasms & Respiratory Pharmacology

12 Renal Physiology & Electrolytes

12.1 Nephron Transport & Renal Physiology 12.2 Electrolyte Disorders 12.3 Acid-Base Physiology & Compensation

13 Renal Pathology

13.1 Glomerular Disease Mechanisms 13.2 Tubulointerstitial, Vascular & Stone Disease

14 Gastrointestinal System

14.1 GI Physiology, Motility & Digestion 14.2 Esophagus, Stomach & Intestinal Pathology 14.3 Liver, Biliary Tree & Pancreas 14.4 GI Microbiology, Nutrition & Malabsorption

15 Endocrine System

15.1 Hormone Signaling & Hypothalamic-Pituitary Axes 15.2 Thyroid & Parathyroid Disease 15.3 Adrenal Disorders & Steroid Pharmacology 15.4 Diabetes, Glucose Homeostasis & Metabolic Syndrome

16 Reproductive System

16.1 Male & Female Reproductive Physiology 16.2 Pregnancy, Placenta & Developmental Toxicology 16.3 Reproductive Pathology & Hormone-Related Neoplasia

17 Multisystem Processes & Disorders

17.1 Cell Injury, Inflammation & Repair 17.2 Neoplasia Principles & Tumor Biology 17.3 Infection, Sepsis & Multisystem Microbial Disease 17.4 Genetics, Inborn Errors & Environmental Toxicology

18 Biostatistics & Epidemiology

18.1 Study Design, Bias & Causation 18.2 Diagnostic Test Metrics & Screening 18.3 Epidemiology Measures & Population Health

19 Social Sciences & Communication

19.1 Ethics Principles & Decision-Making Capacity 19.2 Communication Skills & Difficult Conversations 19.3 Professionalism, Systems & Practice-Based Learning

20 Integrated Disciplines Capstone

20.1 High-Yield Microbiology Anchors Across Systems 20.2 High-Yield Biochemistry & Molecular Mechanisms 20.3 Integrated Pharmacology Strategy & Exam-Day Execution

12.2 Electrolyte Disorders

Key Takeaways Explain This Topic AI

Hyponatremia is categorized by volume status (hypo-/eu-/hypervolemic) and reflects excess free water relative to sodium; hypernatremia reflects free-water deficit (or sodium gain) with impaired thirst or access to water.

Acute K+ shifts into cells are driven by insulin, β2-agonists, and alkalosis; shifts out occur with acidosis, hyperosmolarity, and cell lysis—distinct from total-body K+ depletion or overload.

Magnesium depletion causes refractory hypokalemia and hypocalcemia (impaired PTH release/action); always correct Mg2+ when K+ will not rise.

Calcium–phosphate balance is governed by PTH (↑ bone resorption, ↑ renal Ca reabsorb, ↑ 1α-hydroxylase) and 1,25-(OH)2-vitamin D (↑ gut Ca/PO4 absorption).

Bartter mimics loop diuretics (NKCC2), Gitelman mimics thiazides (NCC), and Liddle is ENaC gain-of-function (hypertension, low aldosterone, hypokalemia).

Last updated: August 2026

12.2 Electrolyte Disorders

Quick Answer: Classify sodium disorders by plasma osmolality and volume (hypo/eu/hypervolemic hyponatremia; hypernatremia = free-water deficit). Separate potassium shifts (insulin, β2-agonists, pH) from total-body K+ changes. Use the PTH–vitamin D axis for Ca/PO4, correct Mg2+ in refractory hypokalemia, and match Bartter/Gitelman/Liddle to NKCC2/NCC/ENaC.

Electrolyte questions almost always hide a volume, acid–base, or hormone clue. Translate the vignette into: (1) water vs sodium balance, (2) shift vs total body store, (3) which transporter or hormone is mis-set.

Plasma Sodium and Body Water

Plasma [Na+] is the main determinant of plasma osmolality (Posm ≈ 2[Na+] + glucose/18 + BUN/2.8 in common clinical units). Hyponatremia usually means relative excess free water ; hypernatremia means relative free-water deficit (or, less often, pure Na+ gain).

Normal plasma Na+ is about 135–145 mEq/L . Symptoms (confusion, seizures) correlate more with acuity and degree than with a single cutoff; chronic adaptive lowering of brain osmolytes means overly rapid correction of chronic hyponatremia risks osmotic demyelination, while delayed correction of severe acute hyponatremia risks cerebral edema—clinical management details vary, but the physiology of brain water is the tested concept.

Hyponatremia by Volume Status

Category Effective volume ADH? Examples Urinary Na+ (typical teaching)

Hypovolemic Low (true volume depletion) Yes (baroreceptor) GI losses + hypotonic replacement; skin losses; diuretics Low if extrarenal losses; high if renal Na+ loss (diuretics, salt wasting)

Euvolemic Clinically normal / mild ↑ TBW Yes (inappropriate or non-osmotic) SIADH , severe hypothyroidism, glucocorticoid deficiency, psychogenic polydipsia (ADH off if pure primary polydipsia) High in SIADH (often >40 mEq/L) with high Uosm

Hypervolemic High total body Na+ and water; low effective arterial blood volume in HF/cirrhosis Yes (low EABV) Heart failure, cirrhosis, nephrosis; also advanced CKD with water intake Low in HF/cirrhosis (secondary hyperaldosteronism); variable in renal failure

SIADH pattern (classic): euvolemic hyponatremia, Posm low, Uosm inappropriately high (e.g., >100 mOsm/kg), urine Na+ not low, normal thyroid/adrenal, and no diuretic. Pathophysiology is ADH-driven free-water reabsorption plus mild volume expansion that increases natriuresis.

Pseudohyponatremia (normal Posm with extreme hyperlipidemia/hyperproteinemia in older assays) and translocational hyponatremia (high glucose or mannitol drawing water into plasma) must be separated from true hypo-osmolar hyponatremia. Corrected Na+ rises ~1.6 mEq/L for each 100 mg/dL glucose above normal in common teaching formulas (some use 2.4)—the exact coefficient is less important than recognizing hyperglycemia lowers measured Na+ by dilution.

Hypernatremia

Hypernatremia ([Na+] >145 mEq/L) means the patient has a free-water deficit relative to sodium, or rarely iatrogenic Na+ gain (hypertonic saline/NaHCO3). Intact thirst and access to water usually prevent sustained hypernatremia; thus hospital patients, infants, and elders with impaired thirst or access dominate vignettes.

  • Mechanism Water balance Examples
  • Hypotonic fluid loss TBW ↓ > Na+ ↓ Osmotic diuresis (glucose, mannitol), loop diuretics, GI losses, burns
  • Pure water loss TBW ↓ Central or nephrogenic diabetes insipidus , insensible losses
  • Sodium gain Na+ ↑ Hypertonic NaHCO3, salt poisoning, seawater

In DI, large volumes of dilute urine persist; desmopressin distinguishes central (responds) from nephrogenic (does not). Lithium is a classic cause of nephrogenic DI via AQP2/pathway impairment.

Potassium: Shifts vs Total-Body Balance

Normal plasma K+ is about 3.5–5.0 mEq/L , but only ~2% of total body K+ is extracellular. Small shifts produce large concentration changes.

Transcellular Shifts (Rapid)

  • Shift K+ into cells (↓ serum K+) Shift K+ out of cells (↑ serum K+)
  • Insulin (stimulates Na/K-ATPase) Insulin deficiency
  • β2-agonists (Na/K-ATPase) β-blockers (lesser effect)
  • Alkalosis Acidosis (especially mineral acidosis; organic acidosis less shift)

Periodic paralysis (hypokalemic, channelopathies) Hyperosmolarity (solvent drag), succinylcholine, digoxin toxicity, cell lysis (rhabdo, tumor lysis)

Exam trap: catecholamine surge or albuterol can drop measured K+ without large total-body depletion. Conversely, succinylcholine or acute mineral acidosis can raise K+ acutely.

Total-Body Potassium Disorders

Hypokalemia causes (total body ↓): GI loss (diarrhea—metabolic acidosis + low K+), skin loss, poor intake (rare alone), and renal loss driven by mineralocorticoid excess, diuretics (loop/thiazide), Bartter/Gitelman, hypomagnesemia, and ampphotericin-like tubular injury. Renal K+ wasting often shows high transtubular K+ gradient / high urine K+ while depleted.

Hyperkalemia causes (total body ↑ or redistribution + impaired excretion): AKI/CKD, hypoaldosteronism ( type 4 RTA pattern), K+-sparing drugs (spironolactone, eplerenone, amiloride, triamterene), ACEI/ARB, trimethoprim (ENaC block), NSAIDs, and massive load/lysis.

Aldosterone and distal Na+ delivery are the twin requirements for K+ secretion: principal cells reabsorb Na+ via ENaC (lumen-negative potential) and secrete K+ via ROMK. Low distal delivery (volume depletion, HF) or ENaC blockade reduces K+ secretion.

Magnesium

Normal serum Mg2+ is roughly 1.7–2.2 mg/dL . Most filtered Mg2+ is reabsorbed in the TAL (paracellular, driven by NKCC2-dependent lumen-positive potential); DCT handles finer regulation.

Hypomagnesemia causes: GI loss, alcohol use, PPIs, loop/thiazide diuretics, calcineurin inhibitors, EGF pathway defects, and Gitelman (DCT Mg wasting). Clinical importance:

Refractory hypokalemia — K+ will not correct until Mg2+ is repleted (ROMK disinhibition when Mg is low promotes K+ secretion).

Hypocalcemia — impaired PTH secretion and end-organ resistance.

Neuromuscular irritability, torsades risk with severe depletion.

Hypermagnesemia is usually iatrogenic (Mg infusions, antacids) in the setting of reduced GFR; it causes diminished reflexes, bradycardia, and hypotension at high levels.

Calcium–Phosphate–PTH–Vitamin D Axis

Hormone Source / activation Main effects

PTH Parathyroid (chief cells); stimulated by low Ca2+, high PO4, low 1,25-D ↑ bone resorption; ↑ renal Ca2+ reabsorption (DCT); ↓ renal PO4 reabsorption (PCT NPT2a internalization); ↑ 1α-hydroxylase → 1,25-(OH)2D

  • 1,25-(OH)2-vitamin D Kidney 1α-hydroxylase ↑ intestinal Ca2+ and PO4 absorption; feedback suppresses PTH
  • FGF23 Osteocytes ↓ renal PO4 reabsorption; ↓ 1,25-D (phosphate economy)
  • Calcitonin C cells Minor acute ↓ bone resorption in humans (less CBSE-central)

Hypocalcemia patterns: hypoparathyroidism (low PTH, high PO4), vitamin D deficiency (low/normal Ca, low/normal PO4, high PTH—secondary hyperparathyroidism), CKD (low 1,25-D, high PO4, high PTH), pancreatitis, citrate binding, and hungry bone syndrome.

Hypercalcemia patterns: primary hyperparathyroidism (high/inappropriately normal PTH, high/normal Ca, low/normal PO4), PTHrP malignancy (PTH low), osteolytic mets, excess 1,25-D (granulomatous disease, lymphoma), milk-alkali, thyrotoxicosis, and thiazides (reduce urinary Ca).

Phosphate: Hyperphosphatemia from renal failure, massive lysis, or hypoparathyroidism; hypophosphatemia from refeeding, hungry bone, hyperparathyroidism, FGF23 excess (tumor-induced osteomalacia, XLH), and phosphate binders.

Thiazides decrease urinary calcium (useful in stone formers with hypercalciuria); loops increase urinary calcium (can cause hypocalcemia with prolonged use).

  • Genetic Transporter Lesions vs Diuretic Sites
  • These syndromes are pure mechanism questions—treat them as “endogenous diuretic” or “ENaC stuck on.”

Disorder Defect Mimics BP K+ Acid–base Other

Bartter TAL: NKCC2, ROMK, ClC-Kb, etc. Loop diuretic Low/normal ↓ Metabolic alkalosis Hypercalciuria; may see nephrocalcinosis; high renin/aldosterone

Gitelman DCT: NCC Thiazide Low/normal ↓ Metabolic alkalosis Hypomagnesemia ; hypocalciuria

Liddle ENaC gain-of-function Opposite of amiloride Hypertension ↓ Metabolic alkalosis Low renin and aldosterone; responds to amiloride, not spironolactone

Apparent mineralocorticoid excess / 11β-HSD2 deficiency Cortisol activates MR Mineralocorticoid excess HTN ↓ Alkalosis Low renin/aldosterone

Primary hyperaldosteronism Adrenal aldosterone excess — HTN ↓ Alkalosis Low renin, high aldosterone

Distinguishing Bartter vs Gitelman (exam favorite): both have normotensive hypokalemic metabolic alkalosis with high renin/aldosterone, but Gitelman has prominent hypomagnesemia and hypocalciuria (thiazide-like), whereas classic antenatal/severe Bartter more often shows hypercalciuria (loop-like).

Liddle vs hyperaldosteronism: both hypertensive hypokalemic alkalosis, but Liddle has suppressed aldosterone and responds to ENaC blockade (amiloride/triamterene), not mineralocorticoid receptor blockade alone as the primary fix.

Integrated Approach on Exam Day

Na+: Is Posm low? What is volume status? Is ADH expected or inappropriate?

K+: Is this a shift (insulin, pH, β-agonist, lysis) or total-body change (kidney vs gut, aldosterone state)?

Mg2+: Is refractory hypokalemia/hypocalcemia present?

Ca/PO4: Draw PTH direction and whether vitamin D or FGF23 logic fits.

Genetic/diuretic: Name the transporter before naming the syndrome.

Connect each answer back to the nephron map from section 12.1—electrolyte disorders are applied renal physiology, not free-standing lists.